Zasocitinib for psoriasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Aug 2026: Trial registered, NCT07752108

The trials

NCT07752108: A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis

State
Not started
Phase
Phase 3
People
40 planned
Started
16 Nov 2026
Primary completion
30 May 2027
Arms
Part 1: Zasocitinib 30 mg, Part 2: Zasocitinib 30 mg, Optional Long-Term Extension (LTE): Zasocitinib
Results
None posted
  1. 7 Aug 2026: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as NDI-034858 study drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.